Download PDF
Neuropediatrics 2018; 49(03): 193-199
DOI: 10.1055/s-0038-1637738
Original Article
Georg Thieme Verlag KG Stuttgart · New York

Diagnosis and Treatment of Tuberous Sclerosis Manifestations in Children: A Multicenter Study

Marina Flotats-Bastardas
1   Department of Pediatric Neurology, Saarland University Medical Center, Homburg, Germany
2   Department of Pediatric Neurology, Vall d'Hebron University Hospital, Barcelona, Spain
,
Daniel Ebrahimi-Fakhari
1   Department of Pediatric Neurology, Saarland University Medical Center, Homburg, Germany
,
Ludwig Gortner
3   Department of Pediatrics and Neonatology, Saarland University Medical Center, Homburg, Germany
4   Department of Pediatrics and Neonatology, Medical University Vienna, Vienna, Austria
,
Martin Poryo
5   Department of Pediatric Cardiology, Saarland University Medical Center, Homburg, Germany
,
Michael Zemlin
3   Department of Pediatrics and Neonatology, Saarland University Medical Center, Homburg, Germany
,
Alfons Macaya-Ruiz
2   Department of Pediatric Neurology, Vall d'Hebron University Hospital, Barcelona, Spain
6   Pediatric Neurology Research Group, Vall d'Hebron Research Institute, Barcelona, Spain
,
Sascha Meyer
1   Department of Pediatric Neurology, Saarland University Medical Center, Homburg, Germany
› Author Affiliations
Further Information

Publication History

24 October 2017

06 February 2018

Publication Date:
20 March 2018 (online)

   Permissions and Reprints

Abstract

Tuberous sclerosis complex (TSC) is a genetic disease with a significant morbidity and mortality. We conducted a retrospective analysis of two cohorts (Vall d'Hebron University Hospital [HVH], Barcelona, Spain, 1982–2015, and at Saarland University Medical Center [UKS], Homburg, Germany, 1998–2015) to assess prevalence and treatment of TSC associated manifestations and to evaluate if the follow-up was in line with published recommendations. This was considered if more than 15% of patients did not receive adequate examination with regard to potential organ involvement. A definite diagnosis was made in 52 patients (96%), and a possible diagnosis was made in 2 patients (4%). Thirty-four (63%) patients were from HVH and 20 (37%) from UKS. Median age at first presentation was 6 months (interquartile range: 0–38 months), and median time of follow-up was 6 years (interquartile range: 2–13 years). Clinical symptoms that led to a diagnosis of TSC were cardiac rhabdomyoma (22/54), epilepsy (20/54), and cutaneous manifestations (4/54). Assessment of neuropsychiatric, renal, and ocular manifestations was inadequate in both hospitals, whereas cutaneous manifestation was inadequate at UKS only. Our data demonstrate insufficient examinations in a substantial number of TSC patients with regard to neuropsychiatric, renal, ocular, and cutaneous manifestations. The recently published guidelines may prove valuable in establishing a more comprehensive approach.

Keywords

mTOR - everolimus - SEGA - angiomyolipoma - rhabdomyoma - epilepsy

Ethical Approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.


Informed Consent

Informed consent was obtained from all individual participants included in the study.


Supplementary Material

 

  • References

  • 1 Bourneville DM. Sclérose tubéreuse des circonvolutions cérébrales: Idiote et épilepsie hémiplégique. Arch Neurol 1880; 1: 81-91
    PubMedGoogle Scholar
  • 2 Shepherd CW, Gomez MR, Lie JT, Crowson CS. Causes of death in patients with tuberous sclerosis. Mayo Clin Proc 1991; 66 (08) 792-796
    CrossrefPubMedGoogle Scholar
  • 3 Ebrahimi-Fakhari D, Müller CSL, Altmeyer K. , et al. Tuberöse Sklerose im Kindes- und Jugendalter. Monatsschr Kinderheilkd 2018; 166: 65-78 . doi:10.1007/s00112-017-0353-6
    CrossrefPubMedGoogle Scholar
  • 4 Roach ES, Smith M, Huttenlocher P, Bhat M, Alcorn D, Hawley L. Diagnostic criteria: tuberous sclerosis complex. Report of the Diagnostic Criteria Committee of the National Tuberous Sclerosis Association. J Child Neurol 1992; 7 (02) 221-224
    PubMedGoogle Scholar
  • 5 Roach ES, Gomez MR, Northrup H. Tuberous sclerosis complex consensus conference: revised clinical diagnostic criteria. J Child Neurol 1998; 13 (12) 624-628
    CrossrefPubMedGoogle Scholar
  • 6 Roach ES, DiMario FJ, Kandt RS, Northrup H. ; National Tuberous Sclerosis Association. Tuberous Sclerosis Consensus Conference: recommendations for diagnostic evaluation. J Child Neurol 1999; 14 (06) 401-407
    CrossrefPubMedGoogle Scholar
  • 7 Northrup H, Krueger DA. ; International Tuberous Sclerosis Complex Consensus Group. Tuberous sclerosis complex diagnostic criteria update: recommendations of the 2012 International Tuberous Sclerosis Complex Consensus Conference. Pediatr Neurol 2013; 49 (04) 243-254
    CrossrefPubMedGoogle Scholar
  • 8 Krueger DA, Northrup H. ; International Tuberous Sclerosis Complex Consensus Group. Tuberous sclerosis complex surveillance and management: recommendations of the 2012 International Tuberous Sclerosis Complex Consensus Conference. Pediatr Neurol 2013; 49 (04) 255-265
    CrossrefPubMedGoogle Scholar
  • 9 European Chromosome 16 Tuberous Sclerosis Consortium. Identification and characterization of the tuberous sclerosis gene on chromosome 16. Cell 1993; 75 (07) 1305-1315
    CrossrefPubMedGoogle Scholar
  • 10 van Slegtenhorst M, de Hoogt R, Hermans C. , et al. Identification of the tuberous sclerosis gene TSC1 on chromosome 9q34. Science 1997; 277 (5327): 805-808
    CrossrefPubMedGoogle Scholar
  • 11 Lebwohl D, Anak O, Sahmoud T. , et al. Development of everolimus, a novel oral mTOR inhibitor, across a spectrum of diseases. Ann N Y Acad Sci 2013; 1291: 14-32
    CrossrefPubMedGoogle Scholar
  • 12 Franz DN, Belousova E, Sparagana S. , et al. Efficacy and safety of everolimus for subependymal giant cell astrocytomas associated with tuberous sclerosis complex (EXIST-1): a multicentre, randomised, placebo-controlled phase 3 trial. Lancet 2013; 381 (9861): 125-132
    CrossrefPubMedGoogle Scholar
  • 13 Bissler JJ, Kingswood JC, Radzikowska E. , et al. Everolimus for angiomyolipoma associated with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis (EXIST-2): a multicentre, randomised, double-blind, placebo-controlled trial. Lancet 2013; 381 (9869): 817-824
    CrossrefPubMedGoogle Scholar
  • 14 French JA, Lawson JA, Yapici Z. , et al. Adjunctive everolimus therapy for treatment-resistant focal-onset seizures associated with tuberous sclerosis (EXIST-3): a phase 3, randomised, double-blind, placebo-controlled study. Lancet 2016; 388 (10056): 2153-2163
    CrossrefPubMedGoogle Scholar
  • 15 Franz DN, Capal JK. mTOR inhibitors in the pharmacologic management of tuberous sclerosis complex and their potential role in other rare neurodevelopmental disorders. Orphanet J Rare Dis 2017; 12 (01) 51
    CrossrefPubMedGoogle Scholar
  • 16 Ebrahimi-Fakhari D, Müller CSL, Meyer S, Flotats-Bastardas M, Vogt T, Pföhler C. Topical rapamycin for facial angiofibromas in a child with tuberous sclerosis complex (TSC): a case report and long-term follow-up. Dermatol Ther (Heidelb) 2017; 7 (01) 175-179
    CrossrefPubMedGoogle Scholar
  • 17 Roth J, Roach ES, Bartels U. , et al. Subependymal giant cell astrocytoma: diagnosis, screening, and treatment. Recommendations from the International Tuberous Sclerosis Complex Consensus Conference 2012. Pediatr Neurol 2013; 49 (06) 439-444
    CrossrefPubMedGoogle Scholar
  • 18 Kwan P, Arzimanoglou A, Berg AT. , et al. Definition of drug resistant epilepsy: consensus proposal by the ad hoc Task Force of the ILAE Commission on Therapeutic Strategies. Epilepsia 2010; 51 (06) 1069-1077
    PubMedGoogle Scholar
  • 19 Krueger DA, Wilfong AA, Holland-Bouley K. , et al. Everolimus treatment of refractory epilepsy in tuberous sclerosis complex. Ann Neurol 2013; 74 (05) 679-687
    CrossrefPubMedGoogle Scholar
  • 20 Rosser T, Panigrahy A, McClintock W. The diverse clinical manifestations of tuberous sclerosis complex: a review. Semin Pediatr Neurol 2006; 13 (01) 27-36
    CrossrefPubMedGoogle Scholar
  • 21 Staley BA, Vail EA, Thiele EA. Tuberous sclerosis complex: diagnostic challenges, presenting symptoms, and commonly missed signs. Pediatrics 2011; 127 (01) e117-e125
    CrossrefPubMedGoogle Scholar
  • 22 Kocabaş A, Ekici F, Cetin Iİ. , et al. Cardiac rhabdomyomas associated with tuberous sclerosis complex in 11 children: presentation to outcome. Pediatr Hematol Oncol 2013; 30 (02) 71-79
    CrossrefPubMedGoogle Scholar
  • 23 Mettin RR, Merkenschlager A, Bernhard MK. , et al. Wide spectrum of clinical manifestations in children with tuberous sclerosis complex--follow-up of 20 children. Brain Dev 2014; 36 (04) 306-314
    CrossrefPubMedGoogle Scholar
  • 24 Monteiro T, Garrido C, Pina S. , et al. Tuberous sclerosis: clinical characteristics and their relationship to genotype/phenotype [In Spanish]. An Pediatr (Barc) 2014; 81 (05) 289-296
    CrossrefPubMedGoogle Scholar
  • 25 Au KS, Williams AT, Roach ES. , et al. Genotype/phenotype correlation in 325 individuals referred for a diagnosis of tuberous sclerosis complex in the United States. Genet Med 2007; 9 (02) 88-100
    CrossrefPubMedGoogle Scholar
  • 26 Chu-Shore CJ, Major P, Camposano S, Muzykewicz D, Thiele EA. The natural history of epilepsy in tuberous sclerosis complex. Epilepsia 2010; 51 (07) 1236-1241
    PubMedGoogle Scholar
  • 27 Vignoli A, La Briola F, Turner K. , et al. Epilepsy in TSC: certain etiology does not mean certain prognosis. Epilepsia 2013; 54 (12) 2134-2142
    CrossrefPubMedGoogle Scholar
  • 28 Overwater IE, Bindels-de Heus K, Rietman AB. , et al. Epilepsy in children with tuberous sclerosis complex: Chance of remission and response to antiepileptic drugs. Epilepsia 2015; 56 (08) 1239-1245
    CrossrefPubMedGoogle Scholar
  • 29 Pediamécum. Sultiamo. Comité de Medicamentos de la Asociación Española de Pediatría. http://pediamecum.es/sultiamo . Accessed March 12, 2018
    PubMedGoogle Scholar
  • 30 Rovira À, Ruiz-Falcó ML, García-Esparza E. , et al. Recommendations for the radiological diagnosis and follow-up of neuropathological abnormalities associated with tuberous sclerosis complex. J Neurooncol 2014; 118 (02) 205-223
    CrossrefPubMedGoogle Scholar
  • 31 Jóźwiak S, Mandera M, Młynarski W. Natural history and current treatment options for subependymal giant cell astrocytoma in tuberous sclerosis complex. Semin Pediatr Neurol 2015; 22 (04) 274-281
    CrossrefPubMedGoogle Scholar
  • 32 Jóźwiak S, Nabbout R, Curatolo P. Participants of the TSC Consensus Meeting for SEGA and Epilepsy Management. Management of subependymal giant cell astrocytoma (SEGA) associated with tuberous sclerosis complex (TSC): Clinical recommendations. Eur J Paediatr Neurol 2013; 17 (04) 348-352
    CrossrefPubMedGoogle Scholar
  • 33 Dabora SL, Jozwiak S, Franz DN. , et al. Mutational analysis in a cohort of 224 tuberous sclerosis patients indicates increased severity of TSC2, compared with TSC1, disease in multiple organs. Am J Hum Genet 2001; 68 (01) 64-80
    CrossrefPubMedGoogle Scholar
  • 34 Franz DN, Belousova E, Sparagana S. , et al. Everolimus for subependymal giant cell astrocytoma in patients with tuberous sclerosis complex: 2-year open-label extension of the randomised EXIST-1 study. Lancet Oncol 2014; 15 (13) 1513-1520
    CrossrefPubMedGoogle Scholar
  • 35 Oertel JMK, Baldauf J, Schroeder HWS, Gaab MR. Endoscopic options in children: experience with 134 procedures. J Neurosurg Pediatr 2009; 3 (02) 81-89
    CrossrefPubMedGoogle Scholar
  • 36 Kothare SV, Singh K, Hochman T. , et al. Genotype/phenotype in tuberous sclerosis complex: associations with clinical and radiologic manifestations. Epilepsia 2014; 55 (07) 1020-1024
    CrossrefPubMedGoogle Scholar
  • 37 de Vries PJ, Whittemore VH, Leclezio L. , et al. Tuberous sclerosis associated neuropsychiatric disorders (TAND) and the TAND Checklist. Pediatr Neurol 2015; 52 (01) 25-35
    CrossrefPubMedGoogle Scholar
  • 38 Kingswood C, Bolton P, Crawford P. , et al. The clinical profile of tuberous sclerosis complex (TSC) in the United Kingdom: a retrospective cohort study in the Clinical Practice Research Datalink (CPRD). Eur J Paediatr Neurol 2016; 20 (02) 296-308
    CrossrefPubMedGoogle Scholar
  • 39 Ebrahimi-Fakhari D, Meyer S, Vogt T, Pföhler C, Müller CSL. Dermatological manifestations of tuberous sclerosis complex (TSC). J Dtsch Dermatol Ges 2017; 15 (07) 695-700
    PubMedGoogle Scholar
  • 40 Ebrahimi-Fakhari D, Poryo M, Graf N. , et al. Optimized care in patients with rare diseases: TSC at the Center for Rare Diseases (ZSEUKS) at Saarland University Medical Center, Germany. Klin Padiatr 2017; 229 (06) 311-315
    Article in Thieme ConnectPubMedGoogle Scholar